Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Hydroxyurea tolerated well in sickle cell patients
Dauvergne B et al. FSCDR 2018 (annual meeting of the Foundation for Sickle Cell Disease Research), presentation JSCDH-D-18-00052.
Key clinical point:
Major finding: Of adult participants, 16.9% have experienced hydroxyurea-related adverse events.
Study details: Observational 10-year study of 2,000 adults and children with SCD who were taking hydroxyurea.
Disclosures: The study was sponsored by Addmedica, which markets hydroxyurea as Siklos. Dr. Dauvergne is employed by Addmedica.
Source: Dauvergne B et al. FSCDR 2018 (annual meeting of the Foundation for Sickle Cell Disease Research), presentation JSCDH-D-18-00052.
Citation:
Dauvergne B et al. FSCDR 2018 (annual meeting of the Foundation for Sickle Cell Disease Research), presentation JSCDH-D-18-00052.